Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Recaticimab (SHR-1209) in Primary Hypercholesterolemia
NCT04844125Phase 3Completed
- Sponsor
- Hengrui
- Start
- Apr 2021
- Primary completion
- Aug 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypercholesterolemia comparing SHR-1209 with Placebo (2 arms). Primary endpoint: Percentage change in serum LDL-C levels from baseline at 12 weeks. Started Apr 2021; status: completed.
02
Drugs
recaticimab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT04844125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04844125.